Literature DB >> 21030989

Deal watch: Acceleron and Shire to target the activin receptor pathway for muscular disorders.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21030989     DOI： 10.1038/nrd3308

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

Authors:  Xiaolan Zhou; Jin Lin Wang; John Lu; Yanping Song; Keith S Kwak; Qingsheng Jiao; Robert Rosenfeld; Qing Chen; Thomas Boone; W Scott Simonet; David L Lacey; Alfred L Goldberg; H Q Han
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.